Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Urticaria
ADR ID BADD_A04469
ADR Hierarchy
10      Immune system disorders
10.01      Allergic conditions
10.01.06      Urticarias
10.01.06.001      Urticaria
23      Skin and subcutaneous tissue disorders
23.04      Angioedema and urticaria
23.04.02      Urticarias
23.04.02.001      Urticaria
Description A disorder characterized by an itchy skin eruption characterized by wheals with pale interiors and well-defined red margins. [CTCAE] A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress. [MeSH]
MedDRA Code 10046735
MeSH ID D014581
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE)
Synonym
Acute allergic urticaria | Acute urticaria | Allergic urticaria | Erythema urticarial | Generalised urticarial | Generalised urticarial rash | Histamine-like rash | Hives | Nettle rash | Other specified urticaria | Pharmacological urticaria | Rash urticaria-like | Rash urticarial | Subcutaneous urticaria | Unspecified urticaria | Urticaria | Urticaria acute | Urticaria aggravated | Urticaria NOS | Urticaria subcutaneous | Urticaria, unspecified | Urticarial | Urticarial rash | Urticarial symptom | Urticated rash | Urtication | Welts | Wheals | Generalized urticaria | Urticaria generalised | Urticaria drug-induced | Urticaria localised | Urticaria localized | Generalized urticarial rash | Urticaria recurrent | Generalised urticaria | Atopic urticaria | Urticarias
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02397Zopiclone--
BADD_D02411Voxelotor-
BADD_D02423Fondaparinux0.015789%
BADD_D02432Glycopyrronium--
BADD_D02445Solifenacin0.001441%
BADD_D02449Milnacipran0.000767%
BADD_D02450Crisaborole0.014257%
BADD_D02452Icatibant-
BADD_D02462Methylnaltrexone0.001493%
BADD_D02463Pitavastatin0.004204%
BADD_D02465Aclidinium0.001693%
BADD_D02467Naloxegol0.002986%
BADD_D02473Sodium chloride0.003210%
BADD_D02491Valbenazine0.051897%
BADD_D02496Elagolix0.005160%
BADD_D02500Alpelisib0.002250%
BADD_D02501Sarecycline0.000248%
BADD_D02515Pexidartinib0.000492%
BADD_D02519Netarsudil0.000365%
BADD_D02520Baloxavir marboxil0.005448%
BADD_D02521Sodium zirconium cyclosilicate0.006319%
BADD_D02527Abrocitinib0.001206%
BADD_D02529Atogepant0.000226%
BADD_D02549Deucravacitinib0.004099%
BADD_D02550Diroximel fumarate0.004629%
BADD_D02551Docusate--
BADD_D02556Ferrous cation0.001255%
BADD_D02557Finerenone0.000326%
BADD_D02558Gadolinium cation (3+)-
BADD_D02569Magnesium0.000942%
The 44th Page    First    Pre   44 45    Next   Last    Total 45 Pages
ADReCS-Target
ADR Term Drug Name Target